atomoxetine hydrochloride has been researched along with Obesity in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Azarbarzin, A; Braem, M; Calianese, N; Edwards, BA; Gell, L; Hamilton, GS; Hess, LB; Joosten, SA; Marques, M; Op de Beeck, S; Radmand, R; Redline, S; Sands, SA; Taranto-Montemurro, L; Vanderveken, OM; Vena, D; Verbraecken, J; Wellman, A; White, DP | 1 |
| Anagnostou, E | 1 |
| Albayrak, O; Hebebrand, J; Hinney, A; Pauli-Pott, U; Pott, W | 1 |
| Ball, MP; Buchanan, RW; Feldman, S; Kelly, DL; McMahon, RP; Warren, KR | 1 |
| Constantinescu, CC; Mirbolooki, MR; Mukherjee, J; Pan, ML | 1 |
| Allison, DB; Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM | 1 |
1 review(s) available for atomoxetine hydrochloride and Obesity
| Article | Year |
|---|---|
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Depressants; Central Nervous System Stimulants; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Irritable Mood; Melatonin; Metformin; Methylphenidate; Obesity; Outcome Assessment, Health Care; Precision Medicine; Risperidone; Sleep; Sleep Wake Disorders | 2018 |
2 trial(s) available for atomoxetine hydrochloride and Obesity
| Article | Year |
|---|---|
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Appetite Depressants; Atomoxetine Hydrochloride; Attention; Benzodiazepines; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; Clozapine; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Exercise; Female; Humans; Life Style; Male; Maryland; Middle Aged; Neuropsychological Tests; Obesity; Olanzapine; Propylamines; Psychotic Disorders; Schizophrenia | 2011 |
Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Anti-Obesity Agents; Atomoxetine Hydrochloride; Body Mass Index; Double-Blind Method; Female; Humans; Middle Aged; Obesity; Propylamines; Treatment Outcome; Weight Loss | 2006 |
3 other study(ies) available for atomoxetine hydrochloride and Obesity
| Article | Year |
|---|---|
Clinical polysomnographic methods for estimating pharyngeal collapsibility in obstructive sleep apnea.
Topics: Atomoxetine Hydrochloride; Humans; Male; Obesity; Oxygen; Pharynx; Sleep Apnea, Obstructive | 2022 |
Successful treatment with atomoxetine of an adolescent boy with attention deficit/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Male; Mutation; Obesity; Phenotype; Propylamines; Receptor, Melanocortin, Type 4; Risk Reduction Behavior; Treatment Outcome; Weight Loss | 2013 |
Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity.
Topics: Adipose Tissue, Brown; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Blood Glucose; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18; Male; Norepinephrine Plasma Membrane Transport Proteins; Obesity; Propranolol; Propylamines; Radionuclide Imaging; Rats; Rats, Sprague-Dawley | 2013 |